SCHEMBL14636622

SCHEMBL14636622

CCOC(=O)C1CC(O)CN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 2/20 0.50
ALDH1A1 P00352 2/20 0.49
CYP2C19 P33261 2/20 0.48
HPGD P15428 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.45
NPSR1 Q6W5P4 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HTT P42858 1/20 0.45
PKM P14618 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
GABRA1 P14867 2/20 0.44
GABRG2 P18507 2/20 0.44
GABRB3 P28472 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28390258 0.90 ALDH1A1 (0.58) SMN1; SMN2NPC1RAB9AALDH1A1CYP2C19
SCHEMBL12553776 0.89 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AALDH1A1CYP2C19
SCHEMBL10239911 0.89 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AALDH1A1CYP2C19
SCHEMBL382019 0.89 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AALDH1A1CYP2C19
SCHEMBL376726 0.89 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AALDH1A1CYP2C19
SCHEMBL12553782 0.89 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AALDH1A1CYP2C19
SCHEMBL30069342 0.87 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9AALDH1A1CYP2C19
SCHEMBL4794200 0.86 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9AALDH1A1CYP2C19
SCHEMBL4303084 0.86 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9AALDH1A1CYP2C19
SCHEMBL4303081 0.86 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9AALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2734529-B1 BTK INHIBITORS MERCK SHARP & DOHME (US) 2018-09-05 EP disclosed
US-9718828-B2 BTK Inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-01 US disclosed
US-20170008899-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
US-20140221333-A1 BTK INHIBITORS MERCK SHARP & DOHME B.V. (NL) 2014-08-07 US disclosed
EP-2734529-A1 BTK INHIBITORS Merck Sharp & Dohme Corp. (US) 2014-05-28 EP disclosed
WO-2013010380-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008899-A1 BTK INHIBITORS BTK, SYK, ABL1 SMN1; SMN2 3846/4885NPC1 3286/4885RAB9A 1303/4885
US-20140221333-A1 BTK INHIBITORS BTK, SYK, ABL1 SMN1; SMN2 3577/4885NPC1 3341/4885RAB9A 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.